IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J Immunol Res. 2016;2016:8163803 Authors: Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M Abstract IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, fo...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research

Related Links:

Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus nephritis.1 The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
What are the main challenges asthma patients report in accessing and adhering to treatment?BMC Pulmonary Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Conclusions. The applied diagnostic criteria had no significant effect on the reported rate of ABPA prevalence. PMID: 31702121 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Authors: Authried G, Prasad SC, Rasmussen ER, Bygum A Abstract Summary: A subset of patients with angioedema (AE) and urticaria has histamine releasing autoantibodies. The histamine release test (HR-test) has been used as a tool in chronic urticaria to define the autoimmune subgroup and may possibly guide the clinician to a more personalized therapy, like omalizumab and cyclosporine. The prevalence and value of positive histamine releasing autoantibodies in monosymptomatic AE is sparsely described in the literature. The purpose of this study was to report the prevalence of positive histamine releasing autoantibodie...
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Publication date: Available online 9 November 2019Source: Food ControlAuthor(s): Yanbo Wang, Qinqin Qi, Jinru Zhou, Huan Li, Linglin FuAbstractFish has been recognized as one of the “Big-Eight” allergenic food sources with parvalbumin (PV) being one of the major allergens. Here, we report a novel immunomagnetic beads-derived enzyme-linked immunosorbent assay (ELISA) method which employ antibody functionalized graphene oxide (GO) and gold nanoparticles (AuNPs) to amplify the detection signal of PV. The GO and AuNPs are modified with monoclonal antibody (mAb) and HRP-labeled secondary antibody respectively to det...
Source: Food Control - Category: Food Science Source Type: research
AbstractPurposeIncreased systemic cortisol availability during adult critical illness is determined by reduced binding-proteins and suppressed breakdown rather than elevated ACTH. Dynamics, drivers and prognostic value of hypercortisolism during pediatric critical illness remain scarcely investigated.MethodsThis preplanned secondary analysis of the PEPaNIC-RCT (N = 1440), after excluding 420 children treated with corticosteroids before PICU-admission, documented (a) plasma ACTH, (free)cortisol and cortisol-metabolism at PICU-admission, day-3 and last PICU-day, their prognostic value, and impact of withholding...
Source: Intensive Care Medicine - Category: Intensive Care Source Type: research
DISCUSSION SESSION 1: Food allergy (PD01 –PD05)PD01 Allergen-specific humoral and cellular responses in children who fail egg oral immunotherapy due to allergic reactionsMarta Vazquez-Ortiz, Mariona Pascal, Ana Maria Plaza, Manel JuanPD02 FoxP3 epigenetic features in children with cow milk allergyLorella Paparo, Rita Nocerino, Rosita Aitoro, Ilaria Langella, Antonio Amoroso, Alessia Amoroso, Carmen Di Scala, Roberto Berni CananiPD04 Combined milk and egg allergy in early childhood: let them eat cake?Santanu Maity, Giuseppina Rotiroti, Minal GandhiPD05 Introduction of complementary foods in relation to allergy and gut...
Source: Clinical and Translational Allergy - Category: Allergy & Immunology Source Type: research
Abstract Bioactive lipids are critical regulators of inflammation. Over the last 75 years, these diverse compounds have emerged as clinically-relevant mediators of allergic disease pathophysiology. Animal and human studies have demonstrated the importance of lipid mediators in the development of asthma, allergic rhinitis, urticaria, anaphylaxis, atopic dermatitis, and food allergy. Lipids are critical participants in cell signaling events which influence key physiologic (bronchoconstriction) and immune phenomena (degranulation, chemotaxis, sensitization). Lipid-mediated cellular mechanisms including: (1) for...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Table of Contents A1 Pirfenidone inhibits TGF-b1-induced extracellular matrix production in nasal polyp-derived fibroblasts Jae-Min Shin, Heung-Man Lee, Il-Ho Park A2 The efficacy of a 2-week course of oral steroid in the treatment of chronic spontaneous urticaria refractory to antihistamines Hyun-Sun Yoon, Gyeong Yul Park A3 The altered distribution of follicular t helper cells may predict a more pronounced clinical course of primary sjögren’s syndrome Margit Zeher A4 Betamethasone suppresses Th2 cell development induced by langerhans cell li...
Source: World Allergy Organization Journal - Category: Allergy & Immunology Source Type: research
Abstract The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or ...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Asthma | Corticosteroid Therapy | Dermatitis | Dermatology | Food Allergy | Hay Fever | Hives | Xolair